Stock Track | COMPASS Pathways Soars 5.03% Intraday on FDA Fast-Tracking Psychedelic Drug Research and Regulatory Progress

Stock Track

Apr 24

COMPASS Pathways plc (CMPS) saw its stock price soar 5.03% during intraday trading on Friday. The significant move aligns with broader gains in the psychedelic drug development sector.

The surge follows major regulatory developments. The U.S. Food and Drug Administration announced actions to speed up the development of new treatments for serious mental illness, building on a recent presidential executive order. The agency is issuing special priority vouchers to companies developing psychedelic treatments and plans to release final guidance for sponsors.

Specifically for COMPASS Pathways, the FDA granted the company's rolling review request for its new drug application and selected its COMP360 drug candidate for the Commissioner's National Priority Voucher program for treatment-resistant depression. This program provides benefits including enhanced communications and a shortened 1-2 month review time after NDA filing. Concurrently, analyst firm B. Riley initiated coverage of the company with a Buy rating and a $17 price target, citing its progress toward developing the first FDA-approved psychedelic treatment for depression.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1133085042"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133085042\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133085042?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 23:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133085042","market":"us","top_or_hot":-1,"title":"Stock Track | COMPASS Pathways Soars 5.03% Intraday on FDA Fast-Tracking Psychedelic Drug Research and Regulatory Progress","media":"Stock Track","content":"<p>COMPASS Pathways plc (CMPS) saw its stock price soar 5.03% during intraday trading on Friday. The significant move aligns with broader gains in the psychedelic drug development sector.</p><p>The surge follows major regulatory developments. The U.S. Food and Drug Administration announced actions to speed up the development of new treatments for serious mental illness, building on a recent presidential executive order. The agency is issuing special priority vouchers to companies developing psychedelic treatments and plans to release final guidance for sponsors.</p><p>Specifically for COMPASS Pathways, the FDA granted the company's rolling review request for its new drug application and selected its COMP360 drug candidate for the Commissioner's National Priority Voucher program for treatment-resistant depression. This program provides benefits including enhanced communications and a shortened 1-2 month review time after NDA filing. Concurrently, analyst firm B. Riley initiated coverage of the company with a Buy rating and a $17 price target, citing its progress toward developing the first FDA-approved psychedelic treatment for depression.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | COMPASS Pathways Soars 5.03% Intraday on FDA Fast-Tracking Psychedelic Drug Research and Regulatory Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | COMPASS Pathways Soars 5.03% Intraday on FDA Fast-Tracking Psychedelic Drug Research and Regulatory Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-24 23:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>COMPASS Pathways plc (CMPS) saw its stock price soar 5.03% during intraday trading on Friday. The significant move aligns with broader gains in the psychedelic drug development sector.</p><p>The surge follows major regulatory developments. The U.S. Food and Drug Administration announced actions to speed up the development of new treatments for serious mental illness, building on a recent presidential executive order. The agency is issuing special priority vouchers to companies developing psychedelic treatments and plans to release final guidance for sponsors.</p><p>Specifically for COMPASS Pathways, the FDA granted the company's rolling review request for its new drug application and selected its COMP360 drug candidate for the Commissioner's National Priority Voucher program for treatment-resistant depression. This program provides benefits including enhanced communications and a shortened 1-2 month review time after NDA filing. Concurrently, analyst firm B. Riley initiated coverage of the company with a Buy rating and a $17 price target, citing its progress toward developing the first FDA-approved psychedelic treatment for depression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"","article_id":"1133085042","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133085042","pubTimestamp":1777045972,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"COMPASS Pathways plc (CMPS) saw its stock price soar 5.03% during intraday trading on Friday. The significant move aligns with broader gains in the psychedelic drug development sector.The surge...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc"},"translate_title":"个股追踪|COMPASS Pathways盘中大涨5.03%，因FDA快速跟踪迷幻药研究和监管进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":1},"content_text":"COMPASS Pathways plc (CMPS) saw its stock price soar 5.03% during intraday trading on Friday. The significant move aligns with broader gains in the psychedelic drug development sector.The surge follows major regulatory developments. The U.S. Food and Drug Administration announced actions to speed up the development of new treatments for serious mental illness, building on a recent presidential executive order. The agency is issuing special priority vouchers to companies developing psychedelic treatments and plans to release final guidance for sponsors.Specifically for COMPASS Pathways, the FDA granted the company's rolling review request for its new drug application and selected its COMP360 drug candidate for the Commissioner's National Priority Voucher program for treatment-resistant depression. This program provides benefits including enhanced communications and a shortened 1-2 month review time after NDA filing. Concurrently, analyst firm B. Riley initiated coverage of the company with a Buy rating and a $17 price target, citing its progress toward developing the first FDA-approved psychedelic treatment for depression.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}